The global pharmaceutical industry experienced a 7% decline in patent filings in Q1 2024 compared with the previous quarter. The total number of grants dropped by 8%, resulting in overall patent publications decreasing by 7.6%, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q1 2024 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.
Notably, the number of patent applications in the pharmaceutical industry was 60,029 in Q1 2024, versus 64,994 in the prior quarter. Filings were down 3% year-on-year and increase 7% quarter-on-quarter. This compares to a 3% year-on-year increase in patent grants and 7% decline in quarter-on-quarter.
The top five companies accounted for 3% of patenting activity
Analysis of patenting activity by companies shows that the largest number of patents filed over the last quarter was by F. Hoffmann-La Roche with 510, followed by Zhejiang University with 372 and Johnson & Johnson with 371.
Patenting activity was driven by China with a 39% share of total patent filings
The largest share of patent filings in the pharmaceutical industry in Q1 2024 was in China with 39%, followed by the US (13%) and Japan (8%). The share represented by China was 2% higher than the 36% share it accounted for in Q4 2023.
For further understanding of GlobalData's Pharma: Patents Trends Q1 2024, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.